Sanofi Consumer Healthcare India Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Virtually debt-free
- Regular dividends — yield 1.6%
- Near 52-week low — potential value zone (₹3,168)
Concerns
- High premium to book value (P/B 28x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SANOFICONR · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 60.40% | 71.27% | 71.27% |
| FII | 6.03% | 5.22% | 4.42% | 4.52% | 3.24% | 2.94% |
| DII | 22.60% | 23.83% | 25.35% | 25.48% | 16.89% | 17.21% |
| Public | 10.98% | 10.56% | 9.84% | 9.59% | 8.59% | 8.58% |
Corporate Events
To consider and approve the Unaudited Financial Results for the quarter and nine months ended September 30, 2026
To consider and approve the Unaudited Financial Results for the quarter and half year ended Jun 30, 2026
Dividend - Rs 75 Per Share
Dividend - Rs 55 Per Share
Latest News
All newsSanofi India appoints new management team
*Sanofi India appoints new management team.* The company filed a regulatory update under SEBI LODR, indicating a change in leadership. While no financial figures were disclosed, such shifts can influence strategic direction. The move reflects organizational restructuring at the pharma major. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ManagementChange
Supreme Court dismisses Sanofi India's plea in criminal case
*Supreme Court dismisses Sanofi India's petition to quash criminal proceedings.* The ruling raises legal uncertainty and potential liability for the company. Criminal charges, if pursued, could impact operations and reputation. Investors should monitor for further legal developments. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #LegalCase
Sanofi India reports Q2 and H1 FY26 results
*Sanofi India reports Q2 and H1 FY26 results* released via newspaper publication. Financial performance details for the quarter and half year ended **30th June 2026** are now public. Key metrics like revenue, profit, and guidance will influence near-term trading. Results were in line with regulatory filing norms. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
Sanofi India reports unaudited financial results for Q2 FY26
*Sanofi India reports unaudited financial results for Q2 FY26.* The company released its unaudited financial results for the quarter and half year ended 30th June 2026. Results include key metrics such as revenue and net profit, which will be analyzed for performance trends. Traders may assess guidance and operating margins for near-term positioning. 📊 *STOCKS:* $SANOFIINDIA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
Sanofi India discloses insider trading regulation update
*Sanofi India discloses insider trading regulation update.* The company filed a disclosure under Regulation 7(2)(a) of SEBI's Prohibition of Insider Trading Regulations, 2015. The filing originates from Sanofi Healthcare India Private Limited, part of the promoter group. This is a routine compliance update with no immediate financial impact. 📊 *STOCKS:* SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulation
Sanofi India discloses insider trading regulation update
*Sanofi India discloses insider trading regulation update.* This filing is under Regulation 7(2)(B) of the SEBI (PIT) Regulations, 2015, pertaining to standard compliance disclosures. No **financial figures** or **material events** are mentioned. It is a routine regulatory update. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulation
Sanofi India shares unaffected by regulatory filing update
*Sanofi India shares unchanged after a routine regulatory filing.* The update pertains to compliance under SEBI Listing Regulations, specifically Regulation 30, with no financial impact disclosed. **No material changes** in operations or management were indicated. Such disclosures are standard for listed entities. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulation
Sanofi India issues regulatory filing under SEBI norms
*Sanofi India issues regulatory filing under SEBI norms.* The company has submitted an intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is a routine disclosure with no **specific financial figures** or strategic announcements. Traders should monitor for follow-up updates. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory
Sanofi India hosts analyst call with no major announcements
*Sanofi India hosts analyst call with no major announcements.* The company shared updates during its investor and analyst con. call, focusing on business performance and market outlook. No significant financial revisions or strategic changes were disclosed. Transcript available via NSE corporate filing. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnalystCall
Sanofi India hosts analyst call for investor updates
*Sanofi India hosts analyst call for investor updates.* The company shared insights during its recent investor and analyst meet. A video recording of the session has been made available. No major announcements or financial updates were disclosed. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnalystCall